Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.57 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22549415 | 0.93 | CALCRL (0.54) | SSTR3CALCRLSIRT2SIRT1SIRT3 | |
| SCHEMBL19456877 | 0.90 | SSTR3 (0.54) | SSTR3CALCRLSIRT2SIRT1SIRT3 | |
| SCHEMBL23330068 | 0.89 | CALCRL (0.51) | SSTR3CALCRLSIRT2SIRT1SIRT3 | |
| SCHEMBL24829447 | 0.89 | CALCRL (0.51) | SSTR3CALCRLSIRT2SIRT1SIRT3 | |
| SCHEMBL23230052 | 0.88 | CALCRL (0.60) | SSTR3CALCRLITGB3ITGA2BPSMB5 | |
| SCHEMBL25475432 | 0.86 | SSTR3 (0.54) | SSTR3CALCRLSIRT2SIRT1SIRT3 | |
| SCHEMBL23347260 | 0.85 | CALCRL (0.47) | SSTR3CALCRLSIRT2SIRT1 | |
| SCHEMBL23651238 | 0.85 | CALCRL (0.51) | SSTR3CALCRL | |
| SCHEMBL22267518 | 0.85 | CALCRL (0.49) | SSTR3CALCRLSIRT2SIRT1 | |
| SCHEMBL24450956 | 0.83 | SSTR3 (0.57) | SSTR3CALCRLSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | SSTR3 1768/4885CALCRL 1791/4885SIRT2 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.